JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4251
CALL
Celestica
CLS
$48.8B
| $1.34M | ﹤0.01% |
14,500
-161,200
| -92% | -$12.6M |
2024 Q2
2 quarters
|
|
4252
PUT
NetEase
NTES
$75.1B
| $1.34M | ﹤0.01% |
15,000
| – | – |
2024 Q1
3 quarters
|
|
4253
Herbalife
HLF
$1.32B
| $1.34M | ﹤0.01% |
199,737
-167,859
| -46% | -$1.25M |
2013 Q2
46 quarters
|
|
|
BKV
4254
BKV Corp
BKV
$2.36B
| $1.33M | ﹤0.01% |
+56,087
| New | +$1.14M |
2024 Q4
0 quarters
|
|
4255
Sportradar
SRAD
$3.48B
| $1.33M | ﹤0.01% |
76,890
+24,106
| +46% | +$364K |
2024 Q2
2 quarters
|
|
4256
iShares Fallen Angels USD Bond ETF
FALN
$1.56B
| $1.33M | ﹤0.01% |
49,817
-134,243
| -73% | -$3.63M |
2022 Q1
11 quarters
|
|
4257
MVB Financial
MVBF
$395M
| $1.33M | ﹤0.01% |
64,244
+18,318
| +40% | +$378K |
2018 Q2
26 quarters
|
|
4258
Northern Trust Morningstar Global Upstream Natural Resources ETF
GUNR
$6.89B
| $1.33M | ﹤0.01% |
36,543
+31,865
| +681% | +$1.26M |
2020 Q4
16 quarters
|
|
4259
Hartford Multifactor Developed Markets ex-US ETF
RODM
$1.61B
| $1.33M | ﹤0.01% |
46,733
-5,619
| -11% | -$166K |
2022 Q2
10 quarters
|
|
4260
CALL
Marqeta
MQ
$1.72B
| $1.33M | ﹤0.01% |
+87,500
| New | +$1.54M |
2024 Q4
0 quarters
|
|
4261
Ovid Therapeutics
OVID
$465M
| $1.32M | ﹤0.01% |
1,418,306
-45,532
| -3% | -$51K |
2017 Q4
28 quarters
|
|
4262
Johnson Outdoors
JOUT
$471M
| $1.32M | ﹤0.01% |
40,101
-3,194
| -7% | -$109K |
2017 Q1
31 quarters
|
|
4263
Dimensional Emerging Markets High Profitability ETF
DEHP
$465M
| $1.32M | ﹤0.01% |
53,430
+3,388
| +7% | +$87.6K |
2022 Q4
8 quarters
|
|
4264
ProShares S&P MidCap 400 Dividend Aristocrats ETF
REGL
$1.66B
| $1.32M | ﹤0.01% |
16,377
-178,748
| -92% | -$14.9M |
2022 Q4
8 quarters
|
|
4265
Farmers & Merchants Bancorp
FMAO
$489M
| $1.32M | ﹤0.01% |
44,830
+25,736
| +135% | +$769K |
2017 Q4
28 quarters
|
|
4266
Matrix Service
MTRX
$291M
| $1.32M | ﹤0.01% |
110,181
+19,518
| +22% | +$239K |
2013 Q2
46 quarters
|
|
4267
CALL
General Dynamics
GD
$89.3B
| $1.32M | ﹤0.01% |
5,000
| – | – |
2024 Q3
1 quarter
|
|
|
4268
PUT
General Dynamics
GD
$89.3B
| $1.32M | ﹤0.01% |
5,000
| – | – |
2024 Q3
1 quarter
|
|
4269
Sana Biotechnology
SANA
$865M
| $1.31M | ﹤0.01% |
806,635
-110,538
| -12% | -$330K |
2021 Q1
15 quarters
|
|
4270
PUT
Community Health Systems
CYH
$384M
| $1.31M | ﹤0.01% |
439,400
| – | – |
2024 Q2
2 quarters
|
|
4271
State Street SPDR S&P Emerging Markets Small Cap ETF
EWX
$663M
| $1.31M | ﹤0.01% |
22,359
-3,283
| -13% | -$201K |
2021 Q4
12 quarters
|
|
4272
Kodiak Sciences
KOD
$5.94B
| $1.31M | ﹤0.01% |
131,646
+86,998
| +195% | +$500K |
2018 Q4
24 quarters
|
|
|
ITIC
4273
Investors Title Co
ITIC
$548M
| $1.3M | ﹤0.01% |
5,497
+2,237
| +69% | +$560K |
2017 Q3
29 quarters
|
|
4274
Fidelity MSCI Real Estate Index ETF
FREL
$1.35B
| $1.3M | ﹤0.01% |
48,161
+2,257
| +5% | +$64.6K |
2018 Q2
26 quarters
|
|
|
CTV
4275
DELISTED
Innovid Corp.
CTV
| $1.3M | ﹤0.01% |
420,974
+215,725
| +105% | +$509K |
2022 Q1
11 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.